Uniform MDT (U-MDT) regimen for all leprosy patients - Another example of wishful thinking

Leprosy Review

Volumn 74, Issue 1, 2003, Pages 2-6

  Ji, Baohong ^a   Saunderson, Paul ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b American Leprosy Missions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; CLINICAL FEATURE; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; HOST PARASITE INTERACTION; HUMAN; LEPROSY; LEPROSY CONTROL; MONOTHERAPY; MULTIBACILLARY LEPROSY; MYCOBACTERIUM LEPRAE; NONHUMAN; PAUCIBACILLARY LEPROSY; PUBLICATION; RECURRENCE RISK; SIDE EFFECT; WORLD HEALTH ORGANIZATION;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEPROSTATIC AGENTS; LEPROSY; MALE; PRACTICE GUIDELINES; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 0037347315     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. World Health Organization. Report on third meeting of the WHO Technical Advisory Group on Elimination of Leprosy. WHO/CDS/CPE/CEE/2002-29.
2. WHO Study Group. Chemotherapy of leprosy for control programmes. WHO Technical Report Series, no. 675. World Health Organization, 1982, Geneva.
3. WHO Expert Committee on Leprosy. Seventh Report. WHO Technical Report Series no.874, World Health Organization, 1998, Geneva.
4. World Health Organization. Report on fourth meeting of the WHO Technical Advisory Group on Elimination of Leprosy. WHO/CDS/CPE/CEE/2002-32.
5. Ji B. Accompanied MDT (AMDT) - more questions than answers. Lepr Rev, 2002; 73: 301-307.
6. Dharmendra. Classification. In: Hastings RC (ed) Leprosy. Churxhill Livingstone, Edinburgh, London, Melbourne & New York, 1985, pp. 88-99.
7. Shepard CC. Recent developments in the chemotherapy and chemoprophylaxis of leprosy. Leprologia (Argentine), 1974; 19: 230-236.
8. Grosset JH, Ji B, Guelpa-Lauras CC et al. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr, 1990; 58: 281-295.
9. Ji B. Drug resistance in leprosy - a review. Lepr Rev, 1985; 56: 265-278.
10. Jacobson RR. Treatment. In: Hastings RC (ed) Leprosy. Churxhill Livingstone, Edinburgh, London, Melbourne & New York, 1985, pp. 193-222.
11. WHO Expert Committee on Leprosy. Sixth Report. WHO Technical Report Series no.768, World Health Organization, 1988, Geneva.
12. WHO Study Group. Chemotherapy of leprosy. WHO Technical Report Series, no.847. World Health Organization, 1994, Geneva.
13. Ji B. Does there exist a subgroup of MB patients at greater risk of relapse after MDT? Lepr Rev, 2001; 72: 3-7.
14. Report of the International Leprosy Association Technical Forum. Lepr Rev, June 2002; 73: supplement.
15. Jamet P, Ji B and the Marchoux Chemotherapy Study Group. Relapse after long-term follow up of multibacillary patients treated with WHO multidrug regimen. Int J Lepr, 1995; 63: 195-201.
16. Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr Rev, 2000; 71: 144-153.
17. Ji B. Rifampicin resistant leprosy: a review and a research proposal of a pilot study. Lepr Rev, 2002; 73: 2-8.
18. Ellard GA. Drug compliance in the treatment of leprosy. Lepr Rev, 1981; 52: 201-213.
19. Marchoux Chemotherapy Study Group. Relapse in multibacillary leprosy patients after stopping treatment with rifampin-containing combined regimens. Int J Lepr, 1992; 60: 525-535.
20. Waters MFR. To smear or not to smear? Lepr Rev, 2002; 73: 211-214.
21. Pattyn S, Grillone S. Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy. Lepr Rev, 2002; 73: 245-247.
22. Lockwood D. Infectious diseases: leprosy. www.clinicalevidence.com, 2002.